Clinical Trials on Acute Idiopathic Thrombocytopenic Purpura

Total 500 results

Amgen

Completed

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura

United States, Canada, Australia
GlaxoSmithKline

Completed

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (PETIT)

Purpura, Thrombocytopaenic, Idiopathic

United States, France, Netherlands, Spain, United Kingdom, Canada
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
GlaxoSmithKline

Completed

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Purpura, Thrombocytopaenic, Idiopathic

Germany, Russian Federation
University Hospital, Angers
Ministry of Health, France

Unknown

Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire

Acute Idiopathic Thrombocytopenic Purpura

France
Amgen

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
University Hospital, Bordeaux

Completed

Diagnostic of Chronic Thrombocytopenia (DIATROC)

Chronic Idiopathic Thrombocytopenic Purpura | Congenital Thrombocytopenia
GlaxoSmithKline

Withdrawn

A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.

Purpura, Thrombocytopaenic, Idiopathic
Amgen

Completed

Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura
Amgen

Completed

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura
GlaxoSmithKline

Completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Purpura, Thrombocytopaenic, Idiopathic

United States
GlaxoSmithKline

Completed

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom
GlaxoSmithKline

Completed

Promacta Pregnancy Registry

Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
Amgen

Completed

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

United States, Canada, Australia, Spain
Assiut University
Association for Training, Education, and Research in Hematology, Immunology...

Not yet recruiting

Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

ITP - Immune Thrombocytopenia
Humanity & Health Medical Group Limited

Completed

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenia

Hong Kong
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
Peking Union Medical College
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
Novartis Pharmaceuticals

Completed

Drug Use Investigation for REVOLADE (ITP)

Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Thailand, Korea, Republic of, United Kingdom, New Zealand, Germany, Greece, Hong Kong, Pakistan, Poland, Romania, Russian Federation, Slovenia, Taiwan
Eisai Inc.

Completed

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Idiopathic Thrombocytopenia Purpura

United States
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Chronic Idiopathic Thrombocytopenic Purpura

China
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Mansoura University

Not yet recruiting

Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura (MansouraU)

Immune Thrombocytopenia
Zealand University Hospital
Odense University Hospital; Rigshospitalet, Denmark

Withdrawn

Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Idiopathic Thrombocytopenic Purpura

Denmark
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Withdrawn

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
Eisai Inc.

Completed

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

United States
Bio Products Laboratory

Completed

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura

United States, India, Argentina
Eisai Inc.

Completed

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Idiopathic Thrombocytopenic Purpura (ITP)

United States
PhytoHealth Corporation

Completed

Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Taiwan
Neufeld, Ellis J, MD, PhD
Genentech, Inc.; Biogen; Glaser Pediatric Research Network; Terrana ITP Research...

Completed

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP)

United States
Sohag University

Recruiting

Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP) (microRNAITP)

Primary Immune Thrombocytopenia

Egypt
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Weill Medical College of Cornell University

Terminated

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (Dex/Rituxan)

Idiopathic Thrombocytopenia Purpura

United States
Anthera Pharmaceuticals

Withdrawn

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura
Neufeld, Ellis J, MD, PhD
Terrana ITP Research Fund

Completed

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura

United States
Hematology and Oncology Specialists

Unknown

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Autoimmune Thrombocytopenic Purpura

United States
David Gomez Almaguer

Unknown

Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Thrombotic Thrombocytopenic Purpura | Immune Thrombocytopenia

Mexico
Octapharma

Completed

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Immune Thrombocytopenic Purpura

Austria
Gruppo Italiano Malattie EMatologiche dell'Adulto
Hematology Project Foundation

Recruiting

Investigation on a Dynamic Cohort of Italian Patients With Active ITP (ITP0918)

Idiopathic Thrombocytopenic Purpura

Italy
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Idiopathic Thrombocytopenic Purpura

China
Amgen

Completed

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura

Clinical Trials on Acute Idiopathic Thrombocytopenic Purpura

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations